Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Investor Presentation (February 2022)
32 slides from Caplin Point Laboratories's investor presentation, February 2022
Slide 1: Investor Presentation February 2022
Annexure - 3 Caplin Point Laboratories Ltd. Investor Presentation February 2022 Second Largest wealth creator for the decade ending 2020* *The Economic Times
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Content
Content 1 Q3 & 9MFY22 Highlights 2 Understanding Caplin 3 Growth engines of Caplin 4 More about Caplin Headquarters, Chennai 3
Slide 4: Content: Q3 & 9MFY22 Highlights
Content 1 Q3 & 9MFY22 Highlights 1.1 Q3 & 9MFY22 Highlights 1.2 Update on CAPEX Robust revenue growth coupled with stable 1.3 margins 1.4 P&L for the Quarter 2 Understanding Caplin 3 Growth engines of Caplin 4 More about Caplin CP-I plant at Suthukeny, Puducherry 4
Slide 5: Q3 & 9MFY22 Highlights
Q3 & 9MFY22 Highlights Financial Highlights • Revenue for the 9MFY22 grew by 20% YoY to Rs. 957 Cr • Gross margin for nine months and for the quarter ended Dec’21 expanded by 151 bps and 105 bps to 56.4% and 55.9% respectively • 9MFY22 PAT is at Rs. 228 Cr up 24% YoY • Cash and Cash Surplus at Rs. 6
Slide 6: Update on CAPEX
Update on CAPEX Caplin is venturing on a Capex journey of INR ~430-450 Cr. to expand existing capacities, widen its product portfolio and backward integrate majority of the products Capacity expansion and Oncology Backward Integration Maintenance Capex ► Installation ongoing for Pre-Mixed Bags line,
Slide 7: Robust revenue growth coupled with stable margins
Robust revenue growth coupled with stable margins Total Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) 336 111 79 66 280 90 Q3 FY22 Q3FY21 Q3FY22 Q3FY21 Q3FY22 Q3FY21 Q3FY22 957 322 797 228 257 9M FY22 184 9MFY21 9MFY22 9MFY21 9MFY22 9MFY21 9MFY22 7
Slide 8: P&L for the Quarter and Nine months – Consolidated
P&L for the Quarter and Nine months – Consolidated Value (INR Cr) Q3 FY22 Q3 FY21 YoY (%) Q2 FY22 QoQ (%) 9M FY22 9M FY21 YoY (%) Revenue from Operation 326.20 274.39 18.9% 303.53 7.5% 930.17 782.58 18.9% Other Income 9.54 5.82 8.49 27.24 14.08 Total Revenue 335.74 280.21 19.8% 312.02 7.6% 957.41 79
Slide 9: Content: Understanding Caplin
Content 1 Q3 & 9MFY22 Highlights 2 Understanding Caplin 2.1 Transformation across the decades 2.2 Caplin’s core business Diversified Product Portfolio with a balanced 2.3 product mix Smart mix of manufacturing and outsourcing; 2.4 Product capacities 2.5 Research & Development Capabilities Delivered
Slide 10: Transformation across the decades
Transformation across the decades Started first commercial Started outsourcing from Work on Injectable unit shipments to US China starts Listed on Stock Exchange Entered Angola with Liquid injectable facility unique Stock & Sale Entered the Caribbean gets USFDA Approval Fidelity investment into mode
Slide 11: Our core business – Tapping the untapped markets
Our core business – Tapping the untapped markets Generics and Branded Generics Injectable & Ophthalmic Manufacturing and Export Revenue by Business Segements Generic Branded Generic 75% 25% US Revenue 9%* ~35% Export ~65% Export Headquarters Revenue by Channel Africa LATAM Revenue Pharmacy 3%* Reven
Slide 12: Diversified Product Portfolio with a changing product mix
Diversified Product Portfolio with a changing product mix Diversified Product Portfolio with zero reliance on single product / Therapy 650+ Pharmaceutical formulations 36 Therapeutic Segments Latest focus towards complex spaces Accounts for larger shelf share 4000+ Products Product mix covers over 6
Slide 13: Smart mix of manufacturing, outsourcing; product capacities
Smart mix of manufacturing, outsourcing; product capacities 45% of the products produced inhouse 55% of the products are outsourced from quality conscious partners in India and China Exports India China 65% 35% Total Annual Product Capacity 1,500 Mn 400 Mn 12 Mn Tablets Capsules Pre-Mix Bags 20 Mn 6
Slide 14: Research & Development Capabilities
Research & Development Capabilities 5 Dedicated Facilities INR 1.6 bn Capex R&D Expense API Caplin has 5 dedicated R&D setups (3 Continuous capex investment of over Total R&D Spends (Capex + Opex) is Completed R&D for 22 APIs to be used – DSIR approved and 2 under INR 1.6 bn over last 5 years toward
Slide 15: Delivered Robust Profitable Growth & Returns over the years
Delivered Robust Profitable Growth & Returns over the years Total Revenue EBITDA PAT (INR Cr) (INR Cr) 352 (INR Cr) 1,085 322 301 251 957 905 228 250 215 668 207 177 553 145 412 134 313 96 255 87 177 62 58 39 41 26 FY14 FY15 FY16* FY17 FY18 FY19 FY20 FY21 9MFY22 FY14 FY15 FY16* FY17 FY18 FY19 FY20 F
Slide 16: Content
Content 1 Q3 & 9MFY22 Highlights 2 Understanding Caplin 3 Growth Engines of Caplin 4 Appendix Amaris Clinical - CRO Clinic, Chennai 16
Slide 17: Caplin’s Growth Engines
Caplin’s Growth Engines Core business to grow at historical pace… Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at above industry- average pace with margins expected to improve with increased branded generics business … with US Business to boost
Slide 18: Core business to grow at historical pace…
01 | Core business to grow at historical pace… Overview Performance LATAM Operating Revenue from LATAM + Africa (INR Cr) ▪ No. 1 Indian player in Central America 976 ▪ Increased its LATAM footprint from two countries to 12 countries within a decade 843 799 ▪ Entry into Pharmacy sales through Healthc
Slide 19: Caplin’s Healthcare portal
Caplin’s Healthcare portal 19
Slide 20: … with US business to boost the overall growth…
02 | … with US business to boost the overall growth… Overview Injectable plant Inspection history ▪ Invested ~Rs.450 Crore in Capex and Opex for the 5 years since 2014 through Plant has undergone 3 US FDA, 2 EU GMP audits and 1 ANVISA successfully since 2016 internal accruals to enter the US and Reg
Slide 21: “Capital Plus” partner for Caplin Steriles Ltd.
“Capital Plus” partner for Caplin Steriles Ltd. Transaction Structure Transaction Details Objective ▪ Increase R&D capabilities to include Complex Injectable and Ophthalmic products portfolio and enhance capacities at Plant. ▪ Eight Roads and F-Prime Capital – Fidelity together bring access to a pow
Slide 22: Market opportunity in US
Market opportunity in US ~ $4.2 Bn $670mn Market size of our products approved and under Overall market size of our products in Pipeline, under approval approval and approved Overall market opportunity for Caplin in near future in US is about ~ $4.2 Bn 22
Slide 23: … backed by enhanced value chain…
03 | … backed by enhanced value chain… Our strategic decisions which will help us in scaling up value chain Direct approach Forward integration Backward integration Setting up of CRO Plant to Portal ➢ Direct marketing to ➢ Caplin moves further ➢ API for US business: ➢ CRO wing of Caplin ➢ Proposed e
Slide 24: Amaris Clinical - CRO Division of Caplin Point
Amaris Clinical - CRO Division of Caplin Point Amaris Clinical – Highlights High level of data integrity Cost savings of 72-bed state of compliance through end to Capex of INR 29 ~50% the art facility end automation Cr. internally accrued Technologically advanced Commenced operations in volunteer tr
Slide 25: … Strong balance sheet and…
04 | … Strong balance sheet and… Caplin’s strong balance sheet acts as a anchor for it’s vision of perceiving an ‘Invisible opportunity’ Receivable Days Total Capex (INR Cr) Fixed Asset Turnover Ratio 95 95 94 89 84 76.8 73.3 4.07* 65.2 3.36 3.45 3.49 3.25 48.5 49.8 2.57 2.71 46.6 2.34 1.86 30 25.5
Slide 26: … Expansion into other geographies
05 | … Expansion into other geographies Countries Caplin plans to expand its presence Caplin is expanding its presence in regulated countries, larger markets of Latin America, Russia/CIS markets, China and other Asian Countries 26
Slide 27: Content
Content 1 Q3 & 9MFY22 Highlights 2 Understanding Caplin 3 Growth engines of Caplin 4 More about Caplin 4.1 Experienced and Visionary Board of Directors 4.2 Shareholder Information R&D centre 27
Slide 28: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan Mr. D.P. Mishra Dr. K.C. John Chairman Managing Director Director Independent Director ✓ 30+ Years of experience in ✓ 35+ Years experience in ✓ 30+ years experience in the ✓ 30+ years experience in the pharmaceutica
Slide 29: Experienced and Visionary Board of Directors (cont’d)
Experienced and Visionary Board of Directors (cont’d) D Sathyanarayanan Dr. C K Gariyali, IAS Mr V Thirumalai R Viswanathan Independent Director Independent Director Independent Director Independent Director ✓ 30+ years experience in ✓ Retired IAS Officer and ✓ 50+ years experience in the ✓ Retired
Slide 30: Shareholder Information
Shareholder Information Caplin Shareholding as on 31st December 2021 Share Information (as on 31st December 2021) NSE Ticker CAPLIPOINT Others BSE Ticker 524742 27.77% Market Cap (INR Cr) 6,502 % free-float 31.09% Free-float market cap (INR Cr) 2,022 FII Total Debt (INR Cr) 0.26 2.11% Cash & Cash Eq
Slide 31: Our Products
Our Products Caplin Point Laboratories Limited i CION ELECTROLITICA HIDRATANTE UERO LIQUIDO ORAL |
Slide 32: Investor Relations at Caplin
Investor Relations at Caplin Dinesh RG investor@caplinpoint.net Christensen Advisory Rahul Thakur rthakur@christensenir.com CIN: L24231TN1990PLC019053 | ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET 524742 CAPLIPOINT ©2018, Caplin Point Laboratories Limited – All Rights Reserved. © 2018
Caplin Point Laboratories — Investor Presentation (February 2022) on 6ix